Preparation of RGD4C fused anti-TNFα nanobody and inhibitory activity on triple-negative breast cancer in vivo-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Preparation of RGD4C fused anti-TNFα nanobody and inhibitory activity on triple-negative breast cancer in vivo

Published:2020-11 Issue: Volume:260 Page:118274
ISSN:0024-3205
Container-title:Life Sciences
language:en
Short-container-title:Life Sciences

Author:

Ji Xuemei,Han Tianzhen,Kang Nannan,Huang Song,Liu Yu

Funder

National Natural Science Foundation of China

“Double-First Class” University project

The Innovation Team of the “Double-First Class” Disciplines

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference49 articles.

1. Cancer statistics;RL;CA Cancer J. Clin.,2017

2. Comparison of clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer;Qui;J. Cancer,2016

3. Nanoparticles-based drug delivery and gene therapy for breast cancer: recent advancements and future challenges;Mirza;Semin. Cancer Biol.,2019

4. TNF-α renders macrophages resistant to a range of cancer chemotherapeutic agents through NF-κB-mediated antagonism of apoptosis signalling;Lo;Cancer Lett.,2011

5. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha;Leibovich;Nature,1987

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: the most attractive application of nanobodies;Cancer Cell International;2024-02-10

2. Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer Management;Cancers;2024-01-15

3. Nanobodies in cytokine‑mediated immunotherapy and immunoimaging (Review);International Journal of Molecular Medicine;2023-12-06

4. Nanobodies; new molecular instruments with special specifications for targeting, diagnosis and treatment of triple-negative breast cancer;Cancer Cell International;2022-08-06

5. Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment;Frontiers in Immunology;2022-01-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3